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Clinical and experimental evidence indicates that atypical antipsychotics impair glucose metabolism. We investigated whether clozapine
may directly affect insulin action by analyzing insulin signaling in vitro and in vivo. Clozapine reduced insulin-stimulated glucose uptake in
PC12and inL6cells, representative models ofneuronand skeletal muscle, respectively. Consistently, clozapine reducedinsulin effecton
insulin receptor (IR) by 40% and on IR substrate-1 (IRS1) tyrosine phosphorylation by 60%. Insulin-stimulated Akt phosphorylation was
also reduced by about 40%. Moreover, insulin-dependent phosphorylation of protein kinase C-z (PKC-z) was completely blunted in
clozapine-treated cells. Interestingly, clozapine treatment was accompanied by an insulin-independent increase of Akt phosphorylation,
withnochangeofIR,IRS1,andPKC-zbasalphosphorylation.ThecellularabundanceofPed/Pea-15,anAktsubstrateandinducerofinsulin
resistance,wasalsoincreasedfollowingclozapineexposure,bothintheabsenceandinthepresenceofcyclohexymide,aproteinsynthesis
inhibitor. Similar as in cellular models, in the caudate–putamen and in the tibialis muscle of clozapine-treated C57/BL/KsJ mice, Akt
phosphorylation and Ped/Pea-15 protein levels were increased and PKC-z phosphorylation was decreased. Thus, in these experimental
models, clozapine deranged Akt function and up-regulated Ped/Pea-15, thereby inhibiting insulin stimulation of PKC-z and of glucose
uptake.
J. Cell. Physiol. 227: 1485–1492, 2012.  2011 Wiley Periodicals, Inc.
Schizophrenia is a major highly debilitating psychiatric disorder
withaworldwideprevalenceofabout1%(MueserandMcGurk,
2004). Among schizophrenic patients life expectancy is 20%
shorter than in general population (Newman and Bland, 1991).
Thisisaccountedfor,atleastinpart,bycirculatory,respiratory
and metabolic illnesses (Dynes, 1969; Felker et al., 1996;
Mukherjee et al., 1996; Brown, 1997). Several lines of evidence
have indicated that schizophrenic patients have a higher
prevalenceofimpairedglucosetolerance,insulinresistanceand
type 2 diabetes mellitus than general population (Ryan et al.,
2003; Citrome et al., 2005; Thakore, 2005). A family history of
type 2 diabetes mellitus is found in 18–19% of schizophrenic
patients as compared to 1.2–6.3% in the general population
(Mukherjee et al., 1989; Adams and Marano, 1995). A
combination of genetic and environmental factors, including
lifestyle and medications, is likely to be involved in the
dysregulationofglucosemetabolismobservedinthesepatients
(Citrome and Volavka, 2004; Jin et al., 2004; Lamberti et al.,
2004; Newcomer, 2004; Citrome et al., 2007).
Current evidence indicates that ﬁrst (Perez-Iglesias et al.,
2007) and, at a larger extent, second generation antipsychotics
(or atypical antipsychotics) are associated with the risk of
developing type 2 diabetes mellitus (Wirshing et al., 1998;
Sernyak et al., 2002; Mackin et al., 2005; Haupt and Kane, 2007;
Perez-Iglesias et al., 2007). Nevertheless, the molecular events
underlying their actions are poorly understood.
All antipsychotics share a common mechanism of dopamine
D2 receptor occupancy. The D2 receptor family inhibits
adenylyl cyclase in downstreaming transductional pathway
(Stone and Pilowsky, 2007; Nikam and Awasthi, 2008).
In addition, activation of D2 receptor family stimulates the
assembly of a complex containing b-arrestin2, protein
phosphatase2A(PP2A),andAkt(GiraultandGreengard,2004;
Beaulieuetal.,2005).Akt,alsoknownasproteinkinaseB(PKB),
isaserine–threoninekinase thathasbeenlargelystudied forits
role in growth factor-mediated cell survival, cell-cycle
progression, and transcriptional regulation (Brazil et al., 2004).
Aktplays apivotal role intheregulation ofglucose metabolism.
It is rapidly activated by insulin and, in skeletal muscle cells and
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 2011 WILEY PERIODICALS, INC.adipocytes,itmediatesthetranslocationofglucosetransporter
4(GLUT4)ontotheplasmamembrane(HouandPessin,2007).
Moreover, Akt also participates in the complex mechanism
involved in insulin desensitization (Pirola et al., 2003; Tajmir
etal.,2003;Bertaccaetal.,2005)andprotectionfromapoptosis
(Brazil et al., 2004; Duarte et al., 2008). The molecular
mechanisms elicited by Akt are only partially known. Akt
phosphorylates a wide variety of substrates, including the
antiapoptotic protein Ped/Pea-15 (Trencia et al., 2003).
Ped/Pea-15 is a ubiquitously expressed cytosolic protein
which is modulated by phosphorylation at Ser116, by calcium-
calmodulin kinase II (CaMKII) and Akt and at Ser104 by PKC
(Araujo et al., 1993; Condorelli et al., 1998; Xiao et al., 2002;
Trencia et al., 2003; Perfetti et al., 2007). Increased expression
ofPed/Pea-15hasbeendetectedinpatientswithtype2diabetes
and their ﬁrst-degree relatives (Condorelli et al., 1998;
Valentino et al., 2006). Moreover, transgenic mice
overexpressingPed/Pea-15displayabnormalglucosetolerance,
insulin resistance and increased susceptibility to develop
diabetes following weight gain (Vigliotta et al., 2004).
Overexpression of Ped/Pea-15 in cultured skeletal muscle cells
inhibits insulin-induced activation of protein kinase C-z (PKC-
z), thereby impairing GLUT4 translocation and glucose uptake
(Condorelli et al., 1998, 2001; Vigliotta et al., 2004).
We have hypothesized that PED/PEA-15, which is highly
expressed in brain (Sharif et al., 2004) and plays a major role as
an apoptotic protein (Fiory et al., 2009), might represent a
crucial target for antipsychotics in neurons. On the other end,
raisedlevelsofPED/PEA-15ininsulin-sensitivetissuesmaylead
to insulin resistance, which often accompanies the use of such
drugs. Therefore, we have used the rat pheochromocytoma
PC-12 cells and L6 skeletal muscle cells as a model of brain and
peripheral tissues, respectively. We have measured glucose
uptake in both cell types as a marker of insulin action. Indeed,
bothcelltypeshavetheabilitytouptakeglucoseandtorespond
to insulin-mediated signals (Dikic et al., 1994; Dwyer et al.,
1999; Leney and Tavare ´, 2009). Moreover, whilst glucose
uptake has been extensively investigated in muscle cells, recent
evidence indicates that insulin may also stimulate similar
signaling cascades and translocation of glucose transporters in
speciﬁc brain areas (Grillo et al., 2009).
Here we show, by in vivo and in vitro paradigms, that
clozapine increases Akt activity and Ped/Pea-15 protein
accumulation in PC-12 and L6 cells. This is paralleled by
decreased PKC-z activation and deranged insulin-stimulated
glucose uptake.
Materials and Methods
General
Media, sera, and antibiotics for cell cultures were from Invitrogen
Ltd (Paisley, United Kingdom). Phospho-Ser473 Akt antibodies
were purchased from Cell Signaling Technology (Beverly, MA).
Actin antibody was from Sigma (St. Louis, MO). Antibodies
directed against phospho-PKC-z/PKC-z, Akt, were from Santa
CruzBiotechnology(SantaCruz,CA).Insulinreceptorsubstrate-1
(IRS1), IRS2, and phospho-Tyr antibodies were from Upstate Cell
Signaling Technology (Lake Placid, NY). Antibodies to Ped/pea-15
have been previously described (Condorelli et al., 2001).
Electrophoresis and Western blot reagents were from Bio-Rad
(Richmond, VA). 2-Deoxy-[
14C] glucose and ECL reagents were
from GE Healthcare (Piscataway, NJ). Other reagents were from
Sigma–Aldrich (St. Louis, MO).
Cell culture procedures
PC12 transplantable rat pheochromocytoma cells and L6 cells
were plated and grown in Dulbecco’s modiﬁed Eagle’s medium
(DMEM)containing 10% fetalbovine serum(FBS), 5%horse serum
(for PC12 cells), 100mg/ml streptomycin, and 100IU/ml penicillin
at 378C in a humidiﬁed atmosphere of 95% air and 5% CO2.
Drug preparation
Clozapine was a generous gift of Novartis Pharma (AG,
Switzerland).Thecompoundwasdissolvedindimethylsulfoxideat
the concentration needed, according to previously described
procedures (Kang et al., 2004; Sutton et al., 2007). For in vitro
studies, we have incubated PC12 and L6 cells with raising
concentrations of clozapine (0.1–25mM) for different time points
(6,12,24,and48h)inordertochoosethebesttime/concentration
combination to adopt in our experimental paradigm. Our results
have suggested that the best time/concentration setting in our
experimental model was 1.5mM for 24h. This choice was mainly
determined by the complete absence of cellular toxicity.
2-Deoxy-glucose (2-DG) uptake, immunoprecipitation,
and Western blotting
2-DGuptakewasmeasuredaspreviouslyreported(Espositoetal.,
2008). Brieﬂy, L6 or PC12 cells were incubated in serum-free
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented with
0.2% (w/v) bovine serum albumin for 24h in the presence or
absence of 1.5mM clozapine. Cells were incubated in glucose-free
20mM HEPES, pH 7.4, 140mM NaCl, 2.5mM MgSO4, 5mM KCl,
1mM CaCl2 (HEPES buffer) and exposed or not to raising insulin
concentrations(10–200nMrange)for30min.Glucoseuptakewas
measured by incubating cells with 0.15mM 2-deoxy-D-
[14C]glucose (0.5mCi/assay) for 15min in HEPES buffer. The
reaction was terminated by the addition of 10mM cytochalasin B,
and thecells were washedthree timeswith ice-cold isotonic saline
solution before lysis in 1M NaOH. Incorporated radioactivity was
measuredinaliquidscintillationcounter.Forimmunoprecipitation
experiments, cell lysates were solubilized in lysis buffer containing
50mM HEPES (pH 7.5), 150mM NaCl, 10mM EDTA,
10mMNa4P2O7,2mMsodiumorthovanadate,100mMNaF,1mM
phenylmethylsulfonyl ﬂuoride, 10mg/ml aprotinin, 10mg/ml
leupeptin, pH 7.4, and 1% Triton for 2h at 48C. Lysates were
clariﬁedbycentrifugationat12,000gfor15minat48C,andaliquots
were either immunoprecipitated with the indicated antibodies or
directly separated by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS–PAGE) before analysis by Western blot, as
previously described (Fiory et al., 2004).
Animal care
Three-month-old male C57/BL/KsJ mice were purchased by the
Charles River Laboratories (Milan, Italy). Animals were housed
under 12-h light/12-h dark cycle in a temperature and humidity
controlledcolonyroomandweregivenpelletedfoodandwaterad
libitum in a speciﬁc pathogen-free environment.
Animal treatment
For in vivo studies, Clozapine was purchased by Sigma–Aldrich (St.
Louis, MO). Clozapine was dissolved in lactic acid (0.1% in NaCl),
adjusted to pH 5.5 by adding NaOH and administered
intraperitoneallytotheanimals.Thedoseofclozapineusedinthese
studies was 10mg/kg for 21 days. This dose was chosen according
to previous studies (Cheng et al., 2005), describing that animals
treated with 2mg/kg gained weight more than those treated with
10mg/kg. In agreement with these ﬁndings, we have used 10mg/kg
to limit weight gain-dependent insulin resistance.
Tissue collection and immunoblotting
Two hours after the last injection the mice were decapitated to
obtain protein extracts from cortex and caudate–putamen (CP),
using the rat brain atlas by Paxinos and Watson (1997) as an
anatomical reference (approximately from bregma 6.70 to
4.20mm and from bregma 2.20 to 0.40mm for cortex and CP,
respectively). Tissue samples (cortex, CP, and tibialis muscles)
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808C for subsequent Western blotting. Tissue samples were
homogenized in a Polytron homogenizer (Brinkman Instruments,
Westbury,NY)inT-PERTISSUEproteinextractionreagentbuffer
(25mM bicine, 150Mm sodium chloride (pH 7.6), 1mM
phenylmethylsulfonyl ﬂuoride, 10mg/ml aprotinin, 10mg/ml
leupeptin, pH 7.4) (PIERCE, Rockford, IL) according to the
manufacturer’s instruction. Total homogenates were centrifuged
at 12,000g for 30min at 48C and were subjected to SDS–PAGE
with 10% gels. Proteins separated on the gels were electroblotted
ontonitrocelluloseﬁltersasdescribedaboveandmembraneswere
probed with speciﬁc antibodies, as indicated.
Data analysis
A one-factor analysis of variance (ANOVA) was used to analyze
treatmenteffect.AnysigniﬁcantANOVAwerefurtheranalyzedby
Student–Neuman–Keuls post hoc test to determine the speciﬁcity
of the effect. P values <0.05 were considered statistically
signiﬁcant.
Results
Effect of clozapine on glucose uptake in cultured cells
We have evaluated 2-DG uptake in PC12 cells following
treatment with 1.5mM clozapine for 24h (Fig. 1A). This
concentration,althoughnotfullyconsistentwithinvivo dosage
range, was chosen in agreement with the results of dose–
response and time-course proﬁles (data not shown). In the
absence of insulin, no signiﬁcant change of 2-DG uptake was
induced by clozapine (Fig. 1A). However, insulin effect was
almost completely blunted by clozapine. Comparable results
were obtained following identical treatment of L6 myotubes
(Fig.1B).Indeed,insulinelicited2-DGuptakeupto1.5-and2.1-
fold,respectively,inPC12andinL6cells,whileitfailedtoinduce
signiﬁcant changes in the presence of clozapine (Fig. 1A,B).
Effect of clozapine on insulin signaling in cultured cells
Inordertoinvestigateatwhatlevelinsulinactionwasimpaired,
L6cellshavebeenincubatedwith1.5mMclozapinefor24hand
with 100nM insulin for additional 30min. Concentration and
time were chosen according to the maximal effect obtained in
previous experiments. No signiﬁcant change of the cellular
content of the insulin receptor (IR) and of the IRS1 was
detected by Western blot with speciﬁc antibodies. However,
clozapine-treated cells displayed a reduction of insulin-
stimulated IR (Fig. 2A,B) and IRS1 (Fig. 2A,C) tyrosine
phosphorylation of about 40% and 60%, respectively.
Comparable results were obtained by stimulating PC12 cells
with insulin (Fig. 3).
We also investigated whether PKC-z and Akt, two major
kinases involved in the regulation of glucose uptake, were
affected by clozapine. Protein levels of PKC-z were similar in
untreated cells and in L6 cells exposed to clozapine, while
insulin-induced PKC-z phosphorylation at Thr 410 was almost
abolished (Fig. 4A,B). No signiﬁcant change in basal PKC-z
phosphorylation was detected, instead. Akt cellular content
was also unchanged by clozapine (Fig. 4A). Nevertheless,
insulin-independent phosphorylation at Ser 473 (which
represents an activation marker) was signiﬁcantly increased by
about threefold (Fig. 4A,C). In parallel with the early signaling
steps, insulin effect on Akt phosphorylation was reduced by
40% upon clozapine pre-treatment of the cells. Very consistent
results were obtained in PC12 cells (Fig. 5).
Effect of clozapine on Ped/Pea-15 expression
Next, we addressed whether clozapine may affect the cellular
content of Ped/Pea-15, an Akt substrate (Trencia et al., 2003),
whose overexpression causes insulin resistance in cellular and
animalmodels(Condorellietal.,1998;Vigliottaetal.,2004)and
associates to insulin resistance in humans (Valentino et al.,
2006). Clozapine treatment of L6 cells (Fig. 6A) for 24h
increasedPed/Pea-15cellularlevelsbyabouttwofold.Despitea
reduction in the absolute amount, raised Ped/Pea-15 content
was also observed in the presence of cycloheximide (30mM), a
protein synthesis inhibitor, suggesting that, at least in part,
regulationoccurredatpost-translationallevel.Inthiscondition,
no signiﬁcant evidence of toxicity has been observed (data not
shown). Interestingly, treatment of the cells with 10mM
MG132,rescuedthereductionofPed/Pea-15levelsobservedin
thepresenceofcycloheximide,suggestingthatmostofproteinloss
occurred via proteasomal degradation. At variance, actin levels
remained stable, according to the longer half-life of the protein.
Again similar results were obtained with PC12 cells (Fig. 6B).
Therefore, PC12 and L6 cells were incubated with 1.5mM
clozapine fordifferent time points (6, 12, 24, and 48h),prior to
measure the levels of phosphorylated Akt and Ped/Pea-15. The
time-dependent increase of phosphorylated Akt (Fig. 7A,B)
closely paralleled that of Ped/Pea-15 cellular content
(Fig. 7A,C), in both PC12 and L6 cells.
In vivo effects of clozapine on Akt, Ped/Pea-15,
and PKC-z
In order to verify whether clozapine may induce comparable
changes in vivo, two groups of eight C57/BL/KsJ mice were
treated with clozapine (10mg/kg) or vehicle.
Fig. 1. Clozapine inhibits insulin-stimulated glucose uptake in PC12
andL6cells.2-DeoxyglucoseuptakewasmeasuredinPC12(A)andL6
cells(B)aftertreatmentfor24hwithclozapine(1.5mMasindicated).
Control cells received vehicle (DMSO) instead of drugs. Cells were
then exposed to 10, 100, or 200nM insulin for additional 30min, as
indicated.BarsrepresentthemeansWSDoftriplicatedetermination
in four independent experiments. The signiﬁcant differences
(vs. control) were determined by one factor analysis of variance
(ANOVA). Positive samples were further analyzed by
Student–Neuman–Keuls post hoc test to determine the speciﬁcity of
the effect.
MP<0.05.
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assayedbyWesternblotwithspeciﬁcantibodies.Intheanimals
treated with clozapine, increased levels of phosphorylated Akt
were detected in CP (Fig. 8A), but not in cortex. This was
paralleled by increased Ped/Pea-15 detection (Fig. 8B) and
reduced PKC-z phosphorylation in CP (Fig. 8C). Again, no
difference was detected in cortex of the treated animals.
Similarly, tibialis muscle specimens from clozapine-treated
mice featured increased phosphorylated Akt (Fig. 8A) and Ped/
Pea-15 levels (Fig. 8B) as well as decreased PKC-z
phosphorylation (Fig. 8C), compared to vehicle-treated
controls.
Discussion
Consistent with previous ﬁndings in adipocytes (Vestri et al.,
2007),exposureofPC12andL6cells,representativemodelsof
neuron and skeletal muscle cell, respectively, to clozapine
caused an inhibition of insulin-stimulated glucose uptake.
Clozapine, impaired the early events of insulin signaling,
inhibiting IR tyrosine auto-phosphorylation and kinase activity
and insulin-stimulated Akt phosphorylation. In the absence of
insulin, phosphorylated Akt was increased following treatment
with clozapine. The increased Akt phosphorylation is
consistent with previous observations suggesting that this
protein represents a potential target of antipsychotic drugs
Fig. 2. Effect of clozapine on insulin receptor activity in L6 cells. L6
cells have been incubated with clozapine 1.5mM for 24h and with
insulin 100nM for further 30min. A: Protein extracts were
immunoprecipitated with anti-IR (a-subunit) and IRS-1 antibodies,
subjected to Western blotting with antiphosphotyrosine (p-Tyr), IR
(b-subunit),andIRS-1antibodies, asindicated. Totalcelllysates were
also blotted with antiactin antibodies to ensure equal amounts of
cellular proteins. The blots were revealed by ECL and
autoradiography. The blots shown in (A) are representative of four
independentexperiments.B,C:BarsrepresentthemeansWSDofthe
ratio of the densitometric values obtained for phospho- and total
antibodies. The signiﬁcant differences, were determined byANOVA.
Positive samples were further analyzed by Student–Neuman–Keuls
post hoc test to determine the speciﬁcity of the effect.
MP<0.05.
Fig. 3. Effect of clozapine on insulin receptor activity in PC12 cells.
PC12 cells have been incubated with clozapine 1.5mM for 24h and
with insulin 100nM for further 30min. A: Protein extracts were
immunoprecipitated with anti-IR (a-subunit) and IRS-1 antibodies,
subjected to Western blotting with antiphosphotyrosine (p-Tyr), IR
(b-subunit),andIRS-1antibodies,asindicated. Totalcelllysates were
also blotted with antiactin antibodies to ensure equal amounts of
cellular proteins. The blots were revealed by ECL and
autoradiography. The blots shown in (A) are representative of four
independentexperiments.B,C:BarsrepresentthemeansWSDofthe
ratio of the densitometric values obtained for phospho- and total
antibodies. The signiﬁcant differences, were determined byANOVA.
Positive samples were further analyzed by Student–Neuman–Keuls
post hoc test to determine the speciﬁcity of the effect.
MP<0.05.
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been envisioned as one of the potential schizophrenia
susceptibility genes (Emamian et al., 2004; Lovestone et al.,
2007). Thus, one might speculate, that clozapine could operate
by enhancing Akt function, thereby counteracting the defect in
schizophrenic patients.
However, whether the increase of Akt phosphorylation
inducedbyclozapinemightalsobeinvolvedintheimpairmentof
insulin action on glucose uptake is less intuitive. Indeed, Akt is
rapidly stimulated by insulin and mediates many insulin signals,
including glucose uptake (Brazil et al., 2004; Hou and Pessin,
2007). On the other hand, Akt is also involved in insulin
desensitization (Pirola et al., 2003; Tajmir et al., 2003; Bertacca
et al., 2005), and increased Akt has been detected in several
models of insulin resistance (Pirola et al., 2003; Tajmir et al.,
2003; Bertacca et al., 2005; Chakraborty, 2006). Thus, it could
be hypothesized that long-term treatment with clozapine may
inducepersistentup-regulationofAkt,whichinturnmayimpair
insulin signaling.
One of the potential mechanisms by which Akt may affect
insulin signaling is the increase of Ped/Pea-15 protein stability.
Indeed, Ped/Pea-15 is phosphorylated by Akt at serine 116
(Trencia et al., 2003). This stabilizes the protein, likely
preventing its degradation in the proteasome (Trencia et al.,
2003; Perfetti et al., 2007). Increased expression of Ped/Pea-15
has been associated to type 2 diabetes in humans (Condorelli
et al., 1998; Valentino et al., 2006). Moreover, forced
expressioninmiceandinculturedcellsinhibitsinsulinactionon
glucoseuptakebyimpairingPKC-zactivation(Condorellietal.,
2001; Vigliotta et al., 2004). Interestingly, insulin-stimulated
Fig. 4. EffectofclozapineoninsulinsignalinginL6cells.L6cellshave
beenincubatedwithclozapine1.5mMfor24handwithinsulin 100nM
for further 30min. Cell lysates were blotted with phospho-Ser-473
Akt (p-Akt) or phospho-Thr 410 PKC-z (p-PKC-z) followed by
reblotting with total Akt, PKC-z, and actin antibodies, as indicated.
The blots were revealed by ECL and autoradiography. The blots
shown in (A) are representative of four independent experiments.
B,C: Bars represent the meansWSD of the ratio of the densitometric
values obtained for phospho- and total antibodies. The signiﬁcant
differences, were determined by ANOVA. Positive samples were
further analyzed by Student–Neuman–Keuls post hoc test to
determine the speciﬁcity of the effect.
MP<0.05,
MMP<0.01,
MMMP<0.001.
Fig. 5. Effect of clozapine on insulin signaling in PC12 cells. PC12
cells have been incubated with clozapine 1.5mM for 24h and with
insulin 100nM for further 30min. Cell lysates were blotted with
phospho-Ser-473 Akt (p-Akt) or phospho-Thr 410 PKC-z (p-PKC-z)
followed by reblotting with total Akt, PKC-z, and actin antibodies, as
indicated. The blots were revealed by ECL and autoradiography. The
blots shown in (A) are representative of four independent
experiments. B,C: Bars represent the meansWSD of the ratio of the
densitometric valuesobtained for phospho- andtotalantibodies.The
signiﬁcant differences, were determined by ANOVA. Positive
samples were further analyzed by Student–Neuman–Keuls post hoc
test to determine the speciﬁcity of the effect.
MP<0.05,
MMP<0.01,
MMMP<0.001.
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treated cells, in parallel with the dramatic inhibition of glucose
uptake.
Ped/Pea-15isalsoinvolved intheregulationofapoptoticcell
death. Different experimental ﬁndings have suggested that
over-expression of Ped/Pea-15 protects against stress-induced
apoptosis(Trenciaetal.,2003;Perfettietal.,2007;Eckertetal.,
2008). Thus, it is conceivable that elevated Ped/Pea-15 levels
due to Akt activation, may contribute to the antiapoptotic
action of antipsychotics in speciﬁc subsets of neurons. On the
other hand, raised Ped/Pea-15 levels may contribute as well to
thediabetogenicpotentialofsuchcompounds,impairinginsulin
action in peripheral tissues.
In vivo, increased Akt phosphorylation and Ped/Pea-15
expression and decreased PKC-z phosphorylation have been
detected in the CP and in the tibialis muscles of clozapine-
treatedmice,suggestingthattheskeletalmusclemayrepresent
a direct target for antipsychotics. Overall, the ﬁnding that
clozapine, decreases the early steps of insulin action, that is,
receptorandIRSphosphorylation,isconsistentwiththeimpact
exerted by atypical antipsychotics on glucose tolerance
(Wirshing et al., 1998). Our ﬁndings are also consistent with
previousobservations(Vestrietal.,2007)showingthatatypical
antipsychotics directly modulate insulin action in insulin
responsivetissues.Moreover,therapidonsetofhyperglycemia
in clozapine- or olanzapine-treated patients, without weight
gain, and the restoration of normal glucose metabolism after
antipsychotic discontinuation, support the relevance of direct
peripheral action of antipsychotics and their modulation of
glucose metabolism (Koller et al., 2001; Koller and
Doraiswamy, 2002). In addition, it has been shown that
olanzapine causes impairment of b cell function and insulin
resistanceindogs(Aderetal.,2005).Anotherpossibility,isthat
derangement of glucose metabolism accompanying the
treatment with antipsychotics is due to their action at the level
of central nervous system. In this regard it should be noticed
that serotonin system, which is also affected by atypical
Fig. 6. Clozapine increases Ped/Pea-15 protein abundance. L6 (A)
and PC12 (B) cells have been treated with clozapine 1.5mM for 24h
withorwithoutcycloheximide30mM(CHX)andMG13210mM(MG),
as indicated. Cells were lysed as described in the Materials and
Methods Section and lysates were blotted with anti-Ped/Pea-15
antibody. Equal loading of the samples was ensured by control blot
with antiactin antibodies. The blots were revealed by ECL and
autoradiographyandsubjectedtodensitometricanalysisasdescribed
in the Materials and Methods Section. The blots shown are
representative of four independent experiments. The signiﬁcant
differences (vs. control) were determined by ANOVA. Student–
Neuman–Keuls post hoc test was used to determine speciﬁcity of the
effect.
MMP<0.01,
MMMP<0.001.
Fig. 7. Time-course of clozapine effect on Ped/Pea-15 and Akt in
PC12 andL6cells.ThePC12andL6cellswereincubatedfordifferent
times with increasing concentrations 1.5mM clozapine for 6, 12, 24,
and 48h, as indicated. The cells were lysed as described, subjected to
Western blotting with phospho-Ser-473 Akt (pAkt) and Ped/Pea-15
andreblottingfortotal.Equalloadingofthesampleswasevaluatedby
controlblotwithantiactinantibodies.TheblotswererevealedbyECL
and autoradiography (A). For phosphorylated Akt, values were
expressed as ratio with total Akt levels (B); for Ped/Pea-15 as
arbitrary units derived from densitometric analysis, further
normalized on actin values (C), and shown with the bars. Data
represent the meansWSD from at least three experiments. ANOVA
and Student–Neumans–Keuls post hoc test analysis revealed
signiﬁcant differences from the controls.
MP<0.05.
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1490 PANARIELLO ET AL.antipsychotics, is deeply involved in feeding behavior. Indeed,
animal knockout model of 5-hydroxytryptamine-2C receptor
(5-HT2c) display obesity and altered feeding behavior
(Lebovitz, 2003; Reynolds, 2004). Moreover increased food
intakeandweightgainobservedunderclozapinetreatmentcan
be reversed by D1, D2, 5-HT1b, 5-HT2c, and 5-HT3 agonists,
arguing that dopaminergic and serotoninergic receptors are
involved in antipsychotic-induced weight gain, insulin
resistance, and diabetes (Kaur and Kulkarni, 2002).
Although current literature does not exclude central effects
of antipsychotics in causing impairment in peripheral glucose
metabolism (Lean and Pajonk, 2003; Howes et al., 2004), our
data support the hypothesis that clozapine may directly act on
peripheral tissues, affecting insulin sensitivity.
The mechanisms responsible for clozapine effects are
currently under investigation in our laboratory, and may also
involve the increases of Akt. Indeed, it has been previously
reported that Akt hyper-activation impairs IRS1 function, and
may affect IR activity as well (Brozinick et al., 2003). One might
speculate that a different subcellular localization of Akt
following exposure to clozapine may affect its function toward
speciﬁc substrates rather than others.
In summary, our data suggest that second generation
antipsychotics may contribute to the impairment of glucose
metabolism by interfering with insulin action. Drug-induced
deregulationofAktenhancesthelevelsofPed/Pea-15,which,in
turn, inhibits the activation of atypical PKC-z and prevents
insulin-stimulated glucose uptake.
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